Tagged with IPO

Hong Kong Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were forced to sell assets just to survive, the market roared back in 2025 – reclaiming the top global position for…

China Biosion has built a distinctive position within the new generation of Chinese biotech companies pursuing more capital-efficient, globally connected growth. Built around antibody innovation, early value creation, and selective partnering, the company has positioned itself to compete internationally without absorbing the full financial impact of late-stage development alone. Founder Mingjiu…

Taiwan Leo Shen, General Manager of Heron Neutron, transitioned from PwC and semiconductors to healthcare, leveraging regulatory, operational, and capital-market expertise to scale boron neutron capture therapy (BNCT). Under his leadership, the company has secured IPO-backed expansion in Taiwan, partnerships with hospitals and global players, and a vertically integrated BNCT solution.…

Hong Kong Hong Kong’s capital markets are entering a more dynamic phase, underpinned by a gradual return of international investors, a maturing innovation ecosystem, and targeted reforms aimed at improving market access and efficiency. As Johnson Chui explains, the growing momentum across healthcare, biotech, and technology is reinforcing Hong Kong’s role not…

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

Taiwan Lih-Chung Chien, Chairman of the Taipei Exchange (TPEx), highlights the Exchange’s support for SMEs and innovative sectors via a three-tiered market, flexible IPO rules, and the Technology-Based Enterprise mechanism. Taiwan’s strong clusters in biotech, ICT, and semiconductors, along with supportive policies and active investor participation, make it a compelling destination…

Hong Kong After a challenging few years, the Hong Kong Stock Exchange (HKEX)’s IPO market bounced back strongly in 2025. By the end of Q3 2025, HK listings raised USD 23.9 billion across 66 IPOs (up 192 percent vs the previous year). Pre-revenue biotech listings, predominantly from mainland China, are also up…

USA As the world’s largest stock exchange, the New York Stock Exchange (NYSE) plays a pivotal role in shaping access to capital for healthcare and life sciences companies. Johanna Grossman, PhD, who leads this sector for the NYSE, reflects on her career path, the exchange’s growing footprint in biotech, and the…

China 3D Medicines has charted a deliberate path from domestic clinical execution to global oncology innovation. Since its IPO, the company has sharpened its focus on differentiated assets like Envafolimab, while expanding into radioligand and mRNA-based platforms with broad therapeutic potential. Chairman and CEO Dr John Gong outlines how strategic discipline,…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…